ClinConnect ClinConnect Logo
Search / Trial NCT06750497

Forearm Immobilization in T2D

Launched by WAGENINGEN UNIVERSITY · Dec 19, 2024

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial, titled "Forearm Immobilization in T2D," is studying how temporarily immobilizing the forearm affects how muscles use glucose and amino acids in people with type 2 diabetes (T2D). The researchers want to compare results from individuals with T2D to a control group of people without diabetes to better understand these processes. The trial is currently recruiting participants aged 18 to 65, including both men and women. To qualify, candidates must either have diagnosed T2D or be healthy, maintain a healthy weight, and eat regular meals.

Participants in this study can expect to have their forearm immobilized for a short period, and researchers will monitor how this affects their muscle function and metabolism. It's important to note that there are several health conditions and lifestyle factors that could exclude someone from participating, such as a history of heart disease, smoking, or certain medication use. Overall, this study aims to gather important information that could help improve treatment options for individuals with type 2 diabetes.

Gender

ALL

Eligibility criteria

  • Inclusion criteria
  • Males and females with or without diagnosed type 2 diabetes
  • Use lifestyle changes, metformin, gliclazide, or a combination thereof as oral glucose-lowering treatments for T2D
  • Aged 18-80 years at the time of signing informed consent
  • 18.5 ≥ BMI ≤ 35 kg·m2
  • Exclusion criteria
  • Type 1 or a genetic form of diabetes
  • Any diagnosed cardiovascular (heart) disease or high blood pressure (≥160 mmHg systolic and/or ≥100 mmHg diastolic)
  • Chronic use of any prescribed or over-the-counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) that interact with muscle substrate metabolism (e.g. selective serotonin reuptake inhibitors)
  • Consumption of a low-carbohydrate diet
  • Smoking or chewing tobacco
  • Known anaemia
  • Regular use of dietary protein and/or amino acid supplements (\>3 times per week)
  • Currently involved in a structured progressive resistance training program (\>3 times per week)
  • A personal or family history of thrombosis (clots)
  • Any previous motor disorders or inborn errors in muscle and/or lipid metabolism
  • History of kidney disease
  • History of liver disease
  • Pregnant or breastfeeding
  • History of any drug or alcohol abuse in the past two years
  • Claustrophobia
  • Unable to give consent

About Wageningen University

Wageningen University, a leading institution in the fields of life sciences and agricultural research, is dedicated to advancing knowledge and innovation through robust clinical trials. Renowned for its interdisciplinary approach, the university leverages cutting-edge research methodologies and state-of-the-art facilities to explore critical health and environmental challenges. With a commitment to sustainability and public health, Wageningen University collaborates with various stakeholders to conduct trials that aim to improve health outcomes and promote evidence-based practices in both clinical and community settings. Through its rigorous scientific framework, the university strives to contribute valuable insights that inform policy and enhance overall quality of life.

Locations

Wageningen, Gelderland, Netherlands

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported